LONDON (ShareCast) - (Sharecast News) - Medical technology designer and manufacturer Surgical Innovations Group updated the market on the 'CELLIS' range of products supplied to its UK distribution business, Elemental Healthcare, by Meccellis Biotech, on Wednesday.
The AIM-traded firm said that, following the withdrawal of their previously-held CE mark, Meccellis had now received confirmation of their new CE mark for the complete CELLIS range of biological matrix products used in breast and abdominal wall reconstruction surgery from their Notified Body, PCBC.

That would enable Meccellis and Elemental to resume selling the CELLIS range of products.

Further to that, Elemental and Meccellis had reportedly entered into an extended agreement providing Elemental with exclusive UK distribution rights in respect of the CELLIS range for a period of three years expiring in June 2021, with a subsequent automatic renewal period of two years, subject to meeting minimum purchase obligations.

That agreement, and the new CE mark, covered some "exciting and innovative" new products which were due for launch in the UK market during 2019, the Surgical Innovations board said.

Formal certification was anticipated within four-to-eight weeks, during which period the firm's management were said to be working closely with Meccellis to optimise inventory logistics for the UK market.

The Elemental sales team would engage with UK customers during the time to facilitate orderly replenishment of CELLIS products, once availability information became clear.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE